---
title: Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving
  venetoclax-based non-intensive therapy
date: '2023-08-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37647641/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20230831181054&v=2.17.9.post6+86293ac
source: Blood
description: Assessment of measurable residual disease (MRD) by RT-qPCR is strongly
  prognostic in patients with NPM1-mutated AML treated with intensive chemotherapy,
  however there are no data regarding its utility in venetoclax-based non-intensive
  therapy, despite high efficacy in this genotype. We analysed the prognostic impact
  of NPM1 MRD in an international real-world cohort of 76 previously untreated patients
  with NPM1-mutated AML who achieved CR/CRi following treatment with venetoclax ...
disable_comments: true
---
Assessment of measurable residual disease (MRD) by RT-qPCR is strongly prognostic in patients with NPM1-mutated AML treated with intensive chemotherapy, however there are no data regarding its utility in venetoclax-based non-intensive therapy, despite high efficacy in this genotype. We analysed the prognostic impact of NPM1 MRD in an international real-world cohort of 76 previously untreated patients with NPM1-mutated AML who achieved CR/CRi following treatment with venetoclax ...